Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in FcγRIIIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains of mAb-Ds are hypothesised to be responsible. Quantitative data on 12 Fc-glycosylation features of 23 mAb-Ds (12 clones, 5 produced from multiple cell lines) and one blood donor-derived anti-D Ig were obtained by HPLC and mass spectrometry using 3 methods. Glycosylation of mAb-Ds from human B-lymphoblastoid cell lines (B) was similar to anti-D Ig although fucosylation varied, affecting ADCC activity. In vivo, two B mAb-Ds with 77-81% fucosylation cleared red cells and prevented D-immunisation but less effectively than anti-D Ig. High fucosylation (>89%) of mouse-human heterohybridoma (HH) and Chinese hamster ovary (CHO) mAb-Ds blocked ADCC and clearance. Rat YB2/0 mAb-Ds with <50% fucosylation mediated more efficient ADCC and clearance than anti-D Ig. Galactosylation of B mAb-Ds was 57-83% but 15-58% for rodent mAb-Ds. HH mAb-Ds had non-human sugars. These data reveal high galactosylation like anti-D Ig (>60%) together with lower fucosylation (<60%) as safe features of mAb-Ds for mediating rapid red cell clearance at low doses, to enable effective, inexpensive prophylaxis.
Conflict of interest statement
The authors declare no competing interests.
Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.Vox Sang. 2007 Aug;93(2):99-111. doi: 10.1111/j.1423-0410.2007.00945.x. Vox Sang. 2007. PMID: 17683353 Review.
Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D.Transfusion. 2015 Mar;55(3):553-62. doi: 10.1111/trf.12880. Epub 2014 Sep 19. Transfusion. 2015. PMID: 25234110
Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn.Br J Haematol. 2014 Sep;166(6):936-45. doi: 10.1111/bjh.12965. Epub 2014 Jun 7. Br J Haematol. 2014. PMID: 24909983 Free PMC article.
Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties.Biochemistry (Mosc). 2012 Aug;77(8):925-33. doi: 10.1134/S0006297912080147. Biochemistry (Mosc). 2012. PMID: 22860915
Monoclonal anti-D development programme.Transpl Immunol. 2002 Aug;10(2-3):199-204. doi: 10.1016/s0966-3274(02)00066-7. Transpl Immunol. 2002. PMID: 12216950 Review.